Inceptionr LLC Sells 37,014 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Inceptionr LLC lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 72.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,778 shares of the biopharmaceutical company’s stock after selling 37,014 shares during the period. Inceptionr LLC’s holdings in Amicus Therapeutics were worth $130,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $26,000. KBC Group NV grew its position in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 3,120 shares during the last quarter. Legacy Capital Group California Inc. lifted its stake in shares of Amicus Therapeutics by 20.2% in the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 3,900 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $55,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Amicus Therapeutics by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 6,314 shares during the period.

Analyst Ratings Changes

A number of brokerages have recently issued reports on FOLD. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Down 2.6 %

FOLD stock opened at $8.63 on Tuesday. The stock’s 50 day simple moving average is $9.42 and its 200 day simple moving average is $10.22. Amicus Therapeutics, Inc. has a fifty-two week low of $8.55 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market cap of $2.65 billion, a P/E ratio of -47.94, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.